Výsledky vyhľadávania - "Nivolumab/therapeutic use"

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Autori: Peters, Solange Paz-Ares, Luis G. Reck, Martin a ďalší

Prispievatelia: Peters, Solange Paz-Ares, Luis G. Reck, Martin a ďalší

Zdroj: Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Journal of thoracic oncology, vol. 20, no. 1, pp. 94-108

Predmety: PD-L1, Nivolumab, Non–small cell lung cancer, Humans, Nivolumab/pharmacology, Nivolumab/therapeutic use, Nivolumab/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/mortality, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Lung Neoplasms/mortality, Lung Neoplasms/metabolism, Ipilimumab/pharmacology, Ipilimumab/therapeutic use, Ipilimumab/administration & dosage, Male, Female, Middle Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/metabolism, Aged, Adult, Survival Rate, Aged, 80 and over, Follow-Up Studies, Immunotherapy, Ipilimumab

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39369790
http://hdl.handle.net/10261/390933
https://api.elsevier.com/content/abstract/scopus_id/85208360083
https://serval.unil.ch/resource/serval:BIB_89D370D6F09D.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_89D370D6F09D
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_89D370D6F09D7

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

Autori: Isfort, Susanne Bubnoff, Nikolas von Al-Ali, Haifa Kathrin a ďalší

Zdroj: Ann Hematol

Predmety: Male, 0301 basic medicine, Pyrrolidines, Benzenesulfonamides, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Germany, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Humans, Janus Kinase Inhibitors, Aged, Checkpoint-inhibitor, Aged [MeSH], Fedratinib, Pyrazoles/therapeutic use [MeSH], Myeloproliferative Disorders/drug therapy [MeSH], Sulfonamides/therapeutic use [MeSH], Primary Myelofibrosis/drug therapy [MeSH], Male [MeSH], Benzenesulfonamides [MeSH], Myelofibrosis (MF), Pyrrolidines/therapeutic use [MeSH], Female [MeSH], Janus Kinase 2/antagonists, Janus Kinase 2/genetics [MeSH], Nitriles/therapeutic use [MeSH], Humans [MeSH], Janus Kinase Inhibitors/therapeutic use [MeSH], Middle Aged [MeSH], Sulfonamides/administration, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Nivolumab, Pyrimidines/therapeutic use [MeSH], Myeloproliferative Neoplasms (MPN), Research, Germany [MeSH], Nivolumab/administration, Nivolumab/therapeutic use [MeSH], Disease modification, Sulfonamides, 0303 health sciences, Myeloproliferative Disorders, Middle Aged, Janus Kinase 2, Pyrimidines, Primary Myelofibrosis, Pyrazoles, Female

Popis súboru: pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38967662
https://repository.publisso.de/resource/frl:6518685

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma:Comparison of 3-year data from PRADO and OpACIN-neo

Autori: Reijers, Irene L M Menzies, Alexander M Lopez-Yurda, Marta a ďalší

Zdroj: Reijers, I L M, Menzies, A M, Lopez-Yurda, M, Versluis, J M, Rozeman, E A, Saw, R P M, van Houdt, W J, Kapiteijn, E, van der Veldt, A A M, Suijkerbuijk, K P M, Eriksson, H, Hospers, G A P, Klop, W M C, Torres Acosta, A, Grijpink-Ongering, L, Gonzalez, M, van der Wal, A, Al-Mamgani, A, Spillane, A J, Scolyer, R A, van de Wiel, B A, van Akkooi, A C J, Long, G V & Blank, C U 2025, 'Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma ....

Predmety: Humans, Melanoma/mortality, Neoadjuvant Therapy/mortality, Male, Female, Middle Aged, Neoplasm Staging, Ipilimumab/therapeutic use, Aged, Chemotherapy, Adjuvant, Skin Neoplasms/mortality, Lymph Node Excision, Immune Checkpoint Inhibitors/therapeutic use, Adult, Immunotherapy/methods, Nivolumab/therapeutic use, Precision Medicine/methods, Antineoplastic Combined Chemotherapy Protocols/therapeutic use

Popis súboru: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/39602990; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/a7d83797-0e77-4e1c-9d50-d1c472e1262c; info:eu-repo/semantics/altIdentifier/pissn/0959-8049; info:eu-repo/semantics/altIdentifier/eissn/1879-0852

Dostupnosť: https://hdl.handle.net/11370/a7d83797-0e77-4e1c-9d50-d1c472e1262c
https://research.rug.nl/en/publications/a7d83797-0e77-4e1c-9d50-d1c472e1262c
https://doi.org/10.1016/j.ejca.2024.115141
https://pure.rug.nl/ws/files/1277673260/1-s2.0-S0959804924017489-main.pdf
https://www.scopus.com/pages/publications/85210014804

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel

Autori: Grote, Carolin Bohne, Ann-Sophie Blome, Christine a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Male, Adult, Aged, 80 and over, Skin Neoplasms, Research, Surveys and Questionnaires [MeSH], Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Ipilimumab/administration, Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Melanoma/pathology [MeSH], Quality of Life [MeSH], Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], HrQoL, Female [MeSH], Adult [MeSH], Humans [MeSH], Prospective Studies [MeSH], Ipilimumab/adverse effects [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], ICI, Immune Checkpoint Inhibitors/therapeutic use [MeSH], Distress thermometer, Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Ipilimumab/therapeutic use [MeSH], IBDQ-D, SF-36, Nivolumab/administration, Nivolumab/therapeutic use [MeSH], Middle Aged, Ipilimumab, Nivolumab, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Prospective Studies, Immune Checkpoint Inhibitors, Aged

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39387946
https://repository.publisso.de/resource/frl:6497979

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Autori: Martin Reck Tudor-Eliade Ciuleanu Jong-Seok Lee a ďalší

Prispievatelia: Martin Reck Tudor-Eliade Ciuleanu Jong-Seok Lee a ďalší

Zdroj: Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Journal of thoracic oncology, vol. 18, no. 8, pp. 1055-1069

Predmety: Adult, Lung Neoplasms, Brain Neoplasms, Humans, Nivolumab/pharmacology, Nivolumab/therapeutic use, Ipilimumab/pharmacology, Ipilimumab/therapeutic use, B7-H1 Antigen/metabolism, Lung Neoplasms/pathology, Neoplasm Recurrence, Local/drug therapy, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/chemically induced, Brain Neoplasms/drug therapy, Brain Neoplasms/secondary, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Brain metastases, Intracranial outcomes, Ipilimumab, NSCLC, Nivolumab, B7-H1 Antigen, 3. Good health, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37146754
http://hdl.handle.net/10261/353291
https://serval.unil.ch/resource/serval:BIB_9890E6F11421.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_9890E6F11421
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_9890E6F114218

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands

Autori: Zeijl, M.C.T. van Breeschoten, J. van Wreede, L.C. de a ďalší

Prispievatelia: Zeijl, M.C.T. van Breeschoten, J. van Wreede, L.C. de a ďalší

Zdroj: van Zeijl, M C T, van Breeschoten, J, de Wreede, L C, Wouters, M W J M, Hilarius, D L, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Suijkerbuijk, K P M, Haanen, J B A G & van den Eertwegh, A J M 2023, 'Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands', Journal of Immunotherapy, vol. 46, no. 5, pp. 197-204. https://doi.org/10.1097/CJI.0000000000000468
Journal of Immunotherapy (1997), 46, 5, pp. 197-204

Predmety: Cancer Research, Immunology, Radboud University Medical Center, Brain Neoplasms/drug therapy, POOLED ANALYSIS, Nivolumab/therapeutic use, SDG 3 - Good Health and Well-being, Melanoma/pathology, Antineoplastic Combined Chemotherapy Protocols, Journal Article, Immunology and Allergy, METASTATIC MELANOMA, Humans, Melanoma, Netherlands, Pharmacology, Ipilimumab plus nivolumab, Brain Neoplasms, Antineoplastic Combined Chemotherapy Protocols/adverse effects, real world, Clinical Trial, Ipilimumab, 3. Good health, population-based, Nivolumab, SURVIVAL, immunotherapy, Radboudumc 18: Healthcare improvement science Medical Oncology, Ipilimumab/therapeutic use

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37103470
https://cris.maastrichtuniversity.nl/en/publications/0bab63c2-7c57-472e-b6fd-b12fcc4f0a81
https://doi.org/10.1097/CJI.0000000000000468
https://research.vumc.nl/en/publications/7ee24807-e950-4c44-aff8-949e7f1578bd
https://dspace.library.uu.nl/handle/1874/449093
https://hdl.handle.net/1887/3666123
https://repository.ubn.ru.nl//bitstream/handle/2066/292757/292757.pdf
https://hdl.handle.net/2066/292757

In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients

Autori: Timmerman, Laura M. Hensen, Lobke C.M. van Eijs, Mick J.M. a ďalší

Prispievatelia: Timmerman, Laura M. Hensen, Lobke C.M. van Eijs, Mick J.M. a ďalší

Predmety: Adult, Male, Cancer Research, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Immunology, Interferon-alpha/therapeutic use, Middle Aged, T-Lymphocytes/immunology, Immune Checkpoint Inhibitors/therapeutic use, Cell Proliferation/drug effects, Nivolumab/therapeutic use, Oncology, Journal Article, Humans, Immunology and Allergy, Female, Melanoma/drug therapy, Aged

Popis súboru: application/pdf

Prístupová URL adresa: https://dspace.library.uu.nl/handle/1874/453784

Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients

Autori: A. Gawaz I. Wolff L. Nanz a ďalší

Zdroj: Cancer Immunol Immunother

Predmety: Male, Aged, 80 and over, Skin Neoplasms, Research, Aged, 80 and over [MeSH], Melanoma, ≥ 75 years, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Elderly patients, Melanoma/drug therapy [MeSH], Female [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Melanoma/immunology [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Immune checkpoint inhibitor, Skin Neoplasms/mortality [MeSH], Nivolumab/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Middle Aged, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Chemotherapy, Adjuvant, Humans, Female, Immune Checkpoint Inhibitors, Aged, Retrospective Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38969911
https://repository.publisso.de/resource/frl:6524688

B-Cell Infiltration is Associated with Survival Outcomes Following Programmed Cell Death Protein 1 Inhibition in Head and Neck Squamous Cell Carcinoma

Autori: N. Gavrielatou E. Fortis A. Spathis a ďalší

Zdroj: Annals of oncology, vol. 35, no. 4, pp. 340-350

Predmety: Humans, B7-H1 Antigen, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/genetics, Nivolumab/therapeutic use, Programmed Cell Death 1 Receptor, Prospective Studies, Squamous Cell Carcinoma of Head and Neck/drug therapy, Tumor Microenvironment, B lymphocytes, head and neck neoplasms, immunotherapy, lymphocytes, programmed cell death 1 receptor, tumor infiltrating, Nivolumab, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, 3. Good health

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38159908
https://serval.unil.ch/resource/serval:BIB_77EE6FBCAC5B.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_77EE6FBCAC5B6
https://serval.unil.ch/notice/serval:BIB_77EE6FBCAC5B
https://pergamos.lib.uoa.gr/uoa/dl/object/3484275

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

Autori: Monique K. van der Kooij Arjen Joosse Karijn P. M. Suijkerbuijk a ďalší

Zdroj: van der Kooij, M K, Joosse, A, Suijkerbuijk, K P M, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, van den Eertwegh, A J M, de Groot, J W B, Haanen, J B A G, Hospers, G A P, Piersma, D, van Rijn, R S, van der Veldt, A A M, Vreugdenhil, G, Westgeest, H M, Wouters, M W J M, Dekkers, O M & Kapiteijn, E 2023, 'Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study', British Journal of Cancer, vol. 128, no. 5, pp. 707-710. https://doi.org/10.1038/s41416-022-02088-8
British Journal of Cancer, 128, 5, pp. 707-710

Predmety: Programmed Cell Death 1 Receptor, Radboud University Medical Center, 3. Good health, Nivolumab/therapeutic use, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Nivolumab, Programmed Cell Death 1 Receptor/therapeutic use, SDG 3 - Good Health and Well-being, Humans, Melanoma/drug therapy, Radboudumc 18: Healthcare improvement science Medical Oncology, Melanoma

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36564561
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/290913
https://research.vumc.nl/en/publications/5df93c77-482d-4a8d-b2a6-e68d67960d53
https://hdl.handle.net/1887/3564039
https://repository.ubn.ru.nl//bitstream/handle/2066/290913/290913.pdf
https://hdl.handle.net/2066/290913

Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1

Autori: Caroline Robert Céleste Lebbé Thierry Lesimple a ďalší

Zdroj: Clinical cancer research, vol. 29, no. 5, pp. 858-865

Predmety: Adult, Male, Triptorelin Pamoate, Receptors, Antigen, T-Cell, Prostatic Neoplasms, Androgen Antagonists, Humans, Animals, Mice, Nivolumab/therapeutic use, Androgen Antagonists/adverse effects, Androgens/therapeutic use, Melanoma/drug therapy, Melanoma/pathology, Receptors, Antigen, T-Cell/therapeutic use, 3. Good health, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Androgens, Melanoma

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36516188
https://serval.unil.ch/notice/serval:BIB_04775354DA15
https://serval.unil.ch/resource/serval:BIB_04775354DA15.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_04775354DA151

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142: 4-year follow-up from CheckMate 142

Autori: Andre, T. Lonardi, S. Wong, K.YM. a ďalší

Prispievatelia: Andre, T. Lonardi, S. Wong, K.YM. a ďalší

Zdroj: Annals of Oncology. 33:1052-1060

Predmety: immune checkpoint inhibitor, PSEUDOPROGRESSION, colorectal cancer, DNA Mismatch Repair/genetics, DNA Mismatch Repair, Nivolumab/therapeutic use, 03 medical and health sciences, 0302 clinical medicine, Colonic Neoplasms/drug therapy, 3211 Oncology and carcinogenesis, Antineoplastic Combined Chemotherapy Protocols, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, ipilimumab, nivolumab, Science & Technology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, 3202 Clinical sciences, Colorectal Neoplasms/drug therapy, EUROQOL, Ipilimumab, metastatic, 3. Good health, Cancérologie, Nivolumab, Oncology, Colonic Neoplasms, Microsatellite instability, Microsatellite Instability, MSI-H/dMMR, Colorectal Neoplasms, Life Sciences & Biomedicine, Hématologie, Follow-Up Studies

Popis súboru: 1 full-text file(s): application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35764271
https://lirias.kuleuven.be/handle/20.500.12942/704266
https://doi.org/10.1016/j.annonc.2022.06.008
https://biblio.vub.ac.be/vubir/(0e24bfa2-a6c8-41d7-876b-9702acddb2e6).html

Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy

Autori: Brun, Sinne Søberg Hansen, Torben Frøstrup Wen, Sara Witting Christensen a ďalší

Zdroj: Sci Rep
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)

Predmety: B7-H1 Antigen/metabolism, 0301 basic medicine, Lung Neoplasms, Science, Non-Small-Cell Lung/drug therapy, NSCLC, Antibodies, Monoclonal, Humanized, Antibodies, Article, B7-H1 Antigen, sPD-L1, Nivolumab/therapeutic use, Advanced disease, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Monoclonal, Humans, Lung Neoplasms/drug therapy, Humanized, Anti-PD-1/anti-PD-L1 treatment, Carcinoma, Prognosis, 3. Good health, Nivolumab, Medicine, Biomarkers

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38637655
https://doaj.org/article/de6468f3c6e3447088497815bde82608

A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17–11)

Autori: Hyun Ae Jung Keon-Uk Park Sanghee Cho a ďalší

Prispievatelia: Hyun Ae Jung Keon-Uk Park Sanghee Cho a ďalší

Zdroj: Clinical Cancer Research. 28:4240-4247

Predmety: Programmed Cell Death 1 Receptor, Nasopharyngeal Neoplasms* / genetics, Deoxycytidine, B7-H1 Antigen, 03 medical and health sciences, Nasopharyngeal Carcinoma / drug therapy, 0302 clinical medicine, Artificial Intelligence, Antineoplastic Combined Chemotherapy Protocols / adverse effects, B7-H1 Antigen / analysis, Antineoplastic Combined Chemotherapy Protocols, Humans, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor / therapeutic use, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nivolumab* / therapeutic use, Gemcitabine, Nasopharyngeal Carcinoma / etiology, Nasopharyngeal Neoplasms* / drug therapy, Chromatin, B7-H1 Antigen / genetics, 3. Good health, Deoxycytidine / analogs & derivatives, Nivolumab

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35819451

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Autori: Lim, Michael Weller, Michael Idbaih, Ahmed a ďalší

Prispievatelia: Lim, Michael Weller, Michael Idbaih, Ahmed a ďalší

Zdroj: Neuro Oncol
Neuro-Oncology, vol 24, iss 11

Predmety: Cancer Research, Clinical Trial, Phase III, temozolomide, Nivolumab/therapeutic use, 0302 clinical medicine, Adrenal Cortex Hormones, Medicine and Health Sciences, 1306 Cancer Research, DNA Modification Methylases, Cancer, ddc:610, Brain Neoplasms, Chemoradiotherapy, Glioblastoma/drug therapy, Alkylating, 3. Good health, 2728 Neurology (clinical), Nivolumab, Oncology, 6.1 Pharmaceuticals, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Randomized Controlled Trial, 2730 Oncology, PD-L1, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Clinical Neurology, Clinical Investigations, 610 Medicine & health, Antineoplastic Agents, Brain Neoplasms/drug therapy, Adrenal Cortex Hormones/therapeutic use, MGMT promoter, 03 medical and health sciences, Rare Diseases, [SDV.CAN] Life Sciences [q-bio]/Cancer, Clinical Research, Antineoplastic Agents, Alkylating/therapeutic use, Genetics, Journal Article, Temozolomide, Humans, Oncology & Carcinogenesis, Antineoplastic Agents, Alkylating, nivolumab, Tumor Suppressor Proteins, Neurosciences, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, glioblastoma, Evaluation of treatments and therapeutic interventions, 10040 Clinic for Neurology, Brain Disorders, Brain Cancer, DNA Repair Enzymes, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), Glioblastoma

Popis súboru: application/pdf; ZORA_viewcontent_cgi_article_2004.pdf - application/pdf; application/zip

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35511454
https://dspace.library.uu.nl/handle/1874/446311
https://hal.science/hal-04480061v1
https://doi.org/10.1093/neuonc/noac116
https://hal.science/hal-04480061v1/document
https://escholarship.org/uc/item/3hz1x0kc
https://escholarship.org/content/qt3hz1x0kc/qt3hz1x0kc.pdf

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743: 3-year outcomes from CheckMate 743

Autori: Peters, S. Scherpereel, A. Cornelissen, R. a ďalší

Prispievatelia: Peters, S. Scherpereel, A. Cornelissen, R. a ďalší

Zdroj: Annals of oncology, vol. 33, no. 5, pp. 488-499

Predmety: PD-L1, Adult, [SDV]Life Sciences [q-bio], overall survival, Mesothelioma, Malignant, First-line, Ipilimumab, Progression-Free Survival, 3. Good health, [SDV] Life Sciences [q-bio], immune checkpoint inhibitors, Immune checkpoint inhibitors, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, dual immunotherapy, Dual immunotherapy, Antineoplastic Combined Chemotherapy Protocols, Humans, Overall survival, CTLA-4, first-line, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Ipilimumab/adverse effects, Nivolumab/therapeutic use

Popis súboru: application/pdf; Print-Electronic

Prístupová URL adresa: http://www.annalsofoncology.org/article/S0923753422000837/pdf
https://pubmed.ncbi.nlm.nih.gov/35124183
https://hdl.handle.net/1887/3565037
https://serval.unil.ch/notice/serval:BIB_78CBA16F62E5
https://serval.unil.ch/resource/serval:BIB_78CBA16F62E5.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_78CBA16F62E50
https://www.sciencedirect.com/science/article/pii/S0923753422000837?via=ihub
https://hdl.handle.net/11468/13110

CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer

Autori: De Ruysscher, D. Ramalingam, S. Urbanic, J. a ďalší

Zdroj: Clinical lung cancer, vol. 23, no. 3, pp. e264-e268

Predmety: PD-L1, Lung Neoplasms, Cytotoxic T-lymphocyte antigen-4, Progression-free survival, Antibodies, Monoclonal, Immune checkpoint inhibitor, Chemoradiotherapy, OPEN-LABEL, Ipilimumab, 3. Good health, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Chemoradiation, Carcinoma, Non-Small-Cell Lung, PD-1, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Humans, Ipilimumab/therapeutic use, Lung Neoplasms/pathology, Nivolumab/therapeutic use, PD-1/PD-L1

Popis súboru: application/pdf

Prístupová URL adresa: http://www.clinical-lung-cancer.com/article/S1525730421001868/pdf
https://pubmed.ncbi.nlm.nih.gov/34489161
https://cris.maastrichtuniversity.nl/en/publications/ead2e25c-fb64-4165-a3b2-0343afe3ef0d
https://doi.org/10.1016/j.cllc.2021.07.005
https://www.sciencedirect.com/science/article/pii/S1525730421001868
https://serval.unil.ch/resource/serval:BIB_800C38154E47.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_800C38154E473
https://serval.unil.ch/notice/serval:BIB_800C38154E47

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Autori: Robert J. Motzer David F. McDermott Bernard Escudier a ďalší

Prispievatelia: Robert J. Motzer David F. McDermott Bernard Escudier a ďalší

Zdroj: Cancer
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Motzer, R J, McDermott, D F, Escudier, B, Burotto, M, Choueiri, T K, Hammers, H J, Barthélémy, P, Plimack, E R, Porta, C, George, S, Powles, T, Donskov, F, Gurney, H, Kollmannsberger, C K, Grimm, M O, Barrios, C, Tomita, Y, Castellano, D, Grünwald, V, Rini, B I, McHenry, M B, Lee, C W, McCarthy, J, Ejzykowicz, F & Tannir, N M 2022, 'Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma', Cancer, vol. 128, no. 11, pp. 2085-2097. https://doi.org/10.1002/cncr.34180

Predmety: Male, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Medizin, advanced renal cell carcinoma, long-term follow-up, Original Articles, dual checkpoint inhibition, nivolumab plus ipilimumab, Ipilimumab, CheckMate 214, Kidney Neoplasms, 3. Good health, Nivolumab/therapeutic use, Kidney Neoplasms/drug therapy, Nivolumab, durable response, phase 3, Carcinoma, Renal Cell/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Sunitinib, Humans, Female, Carcinoma, Renal Cell

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35383908
https://hdl.handle.net/20.500.12530/98702
https://pure.au.dk/portal/en/publications/0a9becdb-f346-4c22-a679-2e8c2f921920
https://doi.org/10.1002/cncr.34180
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543316/pdf/CNCR-128-2085.pdf
http://www.scopus.com/inward/record.url?scp=85127785977&partnerID=8YFLogxK

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Autori: Yoon-Koo, Kang Li-Tzong, Chen Min-Hee, Ryu a ďalší

Prispievatelia: Yoon-Koo, Kang Li-Tzong, Chen Min-Hee, Ryu a ďalší

Zdroj: The Lancet Oncology. 23:234-247

Predmety: Adult, Male, 0301 basic medicine, Esophageal Neoplasms / mortality, Esophageal Neoplasms, Receptor, ErbB-2, Stomach Neoplasms / drug therapy, 03 medical and health sciences, 0302 clinical medicine, Esophageal Neoplasms / drug therapy, Nivolumab / therapeutic use, Double-Blind Method, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Aged, Aged, 80 and over, Local / drug therapy, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Esophagogastric Junction, 3. Good health, Neoplasm Recurrence, Nivolumab, ErbB-2 / analysis, Stomach Neoplasms / mortality, Female, Neoplasm Recurrence, Local, Receptor

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35030335

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study: a Danish nationwide real-world study

Autori: Mette T. Mouritzen Karen F. Junker Andreas Carus a ďalší

Zdroj: Mouritzen, M T, Junker, K F, Carus, A, Ladekarl, M, Meldgaard, P, Nielsen, A W M, Livbjerg, A, Larsen, J W, Skuladottir, H, Kristiansen, C, Wedervang, K, Schytte, T, Hansen, K H, Østby, A-C, Frank, M S, Lauritsen, J, Sørensen, J B, Langer, S W, Persson, G F, Andersen, J L, Homann, P H, Kristensen, E B, Drivsholm, L B, Bøgsted, M, Christensen, H S, Pøhl, M & Bjørnhart, B 2022, 'Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study', Acta Oncologica, vol. 61, no. 4, pp. 409-416. https://doi.org/10.1080/0284186X.2021.2023213
Mouritzen, M T, Junker, K F, Carus, A, Ladekarl, M, Meldgaard, P, Nielsen, A W M, Livbjerg, A, Larsen, J W, Skuladottir, H, Kristiansen, C, Wedervang, K, Schytte, T, Hansen, K H, Østby, A C, Frank, M S, Lauritsen, J, Sørensen, J B, Langer, S W, Persson, G F, Andersen, J L, Homann, P H, Kristensen, E B, Drivsholm, L B, Bøgsted, M, Christensen, H S, Pøhl, M & Bjørnhart, B 2022, 'Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC : a Danish nationwide real-world study', Acta Oncologica, vol. 61, no. 4, pp. 409-416. https://doi.org/10.1080/0284186X.2021.2023213
Mouritzen, M T, Junker, K F, Carus, A, Ladekarl, M, Meldgaard, P, Nielsen, A W M, Livbjerg, A, Larsen, J W, Skuladottir, H, Kristiansen, C, Wedervang, K, Schytte, T, Hansen, K H, Østby, A-C, Frank, M S, Lauritsen, J, Sørensen, J B, Langer, S W, Persson, G F, Andersen, J L, Homann, P H, Kristensen, E B, Drivsholm, L B, Bøgsted, M, Christensen, H S, Pøhl, M & Bjørnhart, B 2022, ' Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC : a Danish nationwide real-world study ', Acta Oncologica, vol. 61, no. 4, pp. 409-416 . https://doi.org/10.1080/0284186X.2021.2023213
Mouritzen, M T, Junker, K F, Carus, A, Ladekarl, M, Meldgaard, P, Nielsen, A W M, Livbjerg, A, Larsen, J W, Skuladottir, H, Kristiansen, C, Wedervang, K, Schytte, T, Hansen, K H, Østby, A-C, Frank, M S, Lauritsen, J, Sørensen, J B, Langer, S W, Persson, G F, Andersen, J L, Homann, P H, Kristensen, E B, Drivsholm, L B, Bøgsted, M, Christensen, H S, Pøhl, M & Bjørnhart, B 2022, ' Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC : a Danish nationwide real-world study ', Acta oncologica (Stockholm, Sweden), vol. 61, no. 4, pp. 409-416 . https://doi.org/10.1080/0284186X.2021.2023213

Predmety: Male, Lung Neoplasms, Denmark, immune-checkpoint inhibitors, Cancer immunotherapy, Nivolumab/therapeutic use, 03 medical and health sciences, 0302 clinical medicine, clinical prognostic factors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms/pathology, Humans, real-world evidence, Immune Checkpoint Inhibitors, non-small cell lung cancer, Aged, Retrospective Studies, Carcinoma, Immune Checkpoint Inhibitors/therapeutic use, Denmark/epidemiology, 3. Good health, Nivolumab, Carcinoma, Non-Small-Cell Lung/pathology, Female, Non-Small-Cell Lung/pathology

Popis súboru: application/pdf

Prístupová URL adresa: https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2021.2023213?needAccess=true
https://pubmed.ncbi.nlm.nih.gov/35012430
https://vbn.aau.dk/da/publications/686eb154-1718-4f76-8653-85dceaffd10e
https://vbn.aau.dk/ws/files/468426286/Mouritzen_et_al._2022_._Clinical_features_affecting_efficacy_of_immune_checkpoint_inhibitors_in_pretreated_patients_with_advanced_NSCLC_a_Danish_nationwide_real_world_study.pdf
http://www.scopus.com/inward/record.url?scp=85122754235&partnerID=8YFLogxK
https://doi.org/10.1080/0284186X.2021.2023213
https://pure.au.dk/portal/en/publications/e084f07b-840e-4ec0-b6aa-4514e6233d27
https://curis.ku.dk/ws/files/311214501/Clinical_features_affecting_efficacy_of_immune_checkpoint_inhibitors_in_pretreated_patients_with_advanced_NSCLC_a_Danish_nationwide_real_world_study.pdf
https://findresearcher.sdu.dk:8443/ws/files/200700797/0284186X.2021_1_.pdf
https://portal.findresearcher.sdu.dk/da/publications/8c6be9ea-095e-4935-9a22-294c2237c743
https://doi.org/10.1080/0284186X.2021.2023213
https://pure.au.dk/portal/en/publications/e084f07b-840e-4ec0-b6aa-4514e6233d27
http://www.scopus.com/inward/record.url?scp=85122754235&partnerID=8YFLogxK
https://doi.org/10.1080/0284186X.2021.2023213
https://pure.au.dk/ws/files/330384901/Clinical_features_affecting_efficacy_of_immune_checkpoint_inhibitors_in_pretreated_patients_with_advanced_NSCLC_a_Danish_nationwide_real_world_study.pdf